<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03553485</url>
  </required_header>
  <id_info>
    <org_study_id>1.0_09/01/2018</org_study_id>
    <nct_id>NCT03553485</nct_id>
  </id_info>
  <brief_title>Effects of VNS on RT-induced Inflammation and Prognosis of Patients With NSCLC</brief_title>
  <official_title>Effects of Transcutaneous Auricular Vagal Nerve Stimulation on Radiotherapy-induced Inflammation and Prognosis of Patients With Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vrije Universiteit Brussel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kom Op Tegen Kanker</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Vrije Universiteit Brussel</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Lung cancer (LC) remains a leading cause of death among cancers worldwide. Though
      radiotherapy is one of the most frequently used treatments, it increases side-effects (pain,
      fatigue) and inflammation, possibly leading to further tumorigenesis of surviving cancer
      cells. The purpose of this study is to test the effects of transcutaneous auricular VNS vagal
      nerve stimulation (taVNS), known to reduce inflammation, on radiotherapy-induced inflammation
      and other side-effects in LC patients undergoing radiotherapy.

      In this feasibility study 12 patients with NSCLC stage III (A/B) receiving radiotherapy will
      be enrolled. Our primary endpoint is the effect of vagus nerve stimulation (VNS) on
      inflammatory levels (such as CRP and cytokines), immunological factors (neutrophils,
      monocytes, lymphocytes) and the tumor marker CEA. Our secondary endpoint is the psychological
      well-being and quality of life of the patients during their radiotherapy treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 8, 2018</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cancer prognosis: tumor marker</measure>
    <time_frame>7 weeks</time_frame>
    <description>CEA (µg/mL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cancer prognosis: inflammatory level</measure>
    <time_frame>7 weeks</time_frame>
    <description>CRP (mg/mL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cancer prognosis: inflammatory level</measure>
    <time_frame>7 weeks</time_frame>
    <description>cytokines: IL1, IL2, IL6 and IL8 (pg/mL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cancer prognosis: immunological factors</measure>
    <time_frame>7 weeks</time_frame>
    <description>neutrophil count (x10³/mm³)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Health related Quality of Life</measure>
    <time_frame>7 weeks</time_frame>
    <description>To assess the psychological well-being and quality of life of the patients during their radiotherapy treatment the EORTC QLQ-C30 questionnaire will be used.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Lung Cancer, Non-small Cell</condition>
  <arm_group>
    <arm_group_label>taVNS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment will be carried out twice a day (once before the RT session and 8h later) during 7 weeks. Each treatment takes 30 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Treatment will be carried out twice a day (once before the RT session and 8h later) during 7 weeks. Each treatment takes 30 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcutaneous vagus nerve stimulation</intervention_name>
    <description>The transcutaneous auricular vagus nerve stimulator Parasym consists of a stimulation unit and a dedicated ear electrode. The stimulation unit, having approximately the size of a common mobile phone, sends out the electrical impulses. It is connected with the ear electrode, which patients wear like an earphone. The patient can regulate and adapt the intensity of the stimulation (current intensity) according to his/her individual sensitivity, which can vary from day to day or even over the period of the therapy.</description>
    <arm_group_label>taVNS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham</intervention_name>
    <description>Sham Earclip electrodes are electrodes that appear identical to functioning electrodes, however do not deliver any stimulation due to removed wiring.</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>Standard treatment for included patients</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>taVNS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients &gt;18 years old

          -  Patients with non-small cell lung cancer stage III (A or B)

          -  Patients receiving radiotherapy or chemoradiotherapy

          -  Patients with an HRV &lt; 70 msec

        Exclusion Criteria:

          -  Patients with an active implantable medical device, such as a pacemaker, hearing aid
             implant or any other implanted electronic device

          -  Patients with an implanted or wearable defibrillator.

          -  Patients with myocardial disease

          -  Patients with arrhythmias

          -  Patients with an implanted metallic or electronic device in their head.

          -  Pregnant or breastfeeding women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Reijmen, Dra</last_name>
    <role>Principal Investigator</role>
    <affiliation>VUB</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reijmen, Dra</last_name>
    <phone>+32498254615</phone>
    <email>eva.nina.reijmen@vub.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>UZ Brussels</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reijmen, Dra</last_name>
      <phone>+32498254615</phone>
      <email>eva.nina.reijmen@vub.be</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>May 11, 2018</study_first_submitted>
  <study_first_submitted_qc>May 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 12, 2018</study_first_posted>
  <last_update_submitted>June 24, 2019</last_update_submitted>
  <last_update_submitted_qc>June 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vrije Universiteit Brussel</investigator_affiliation>
    <investigator_full_name>Reijmen Eva</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

